4D Molecular Therapeutics Inc. Stock Price, News & Analysis

4D Molecular Therapeutics (FDMT) announced updated interim clinical data for its 4D-310 Phase 1/2 trial aimed at treating Fabry disease. The presentation is scheduled for February 9, 2022, at the 18th Annual WORLD Symposium. 4D-310 utilizes the evolved C102 vector to deliver a functional GLA gene, potentially addressing unmet medical needs in Fabry patients suffering from life-threatening complications. The trial aims to demonstrate improved AGA enzyme levels, enhancing patients' quality of life and offering a novel therapeutic option beyond current enzyme replacement therapies.

4D Molecular Therapeutics (NASDAQ: FDMT) received Fast Track Designation from the FDA for its product candidate 4D-125 to treat inherited retinal dystrophies caused by defects in the RPGR gene. This designation aims to expedite development for serious conditions lacking approved treatments, providing 4DMT with closer communication with the FDA. 4D-125 is currently in a Phase 1/2 clinical trial to assess safety and clinical activity, catering to the urgent need for therapies for X-linked Retinitis Pigmentosa (XLRP), which affects an estimated 24,000 patients in the U.S. alone.

4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) has announced the dosing of the first patient in its Phase 1/2 clinical trial of 4D-150, a gene therapy for neovascular age-related macular degeneration (wet AMD). This milestone is part of a trial expected to enroll approximately 60 adults, evaluating 4D-150's safety and efficacy. 4D-150 aims to inhibit multiple angiogenic factors with a single low dose, addressing treatment burdens faced by patients. The therapy shows promise in providing long-term benefits after intravitreal administration, leveraging the company's proprietary R100 capsid technology.

4D Molecular Therapeutics (Nasdaq: FDMT) announced participation in a fireside chat at the Evercore ISI HealthCONx 2021 Conference on December 2, 2021, at 10:55 a.m. ET. This event offers insights into the company's advances in gene therapy.

A live audio webcast will be accessible via the Investors & Media section on the company's website, with a replay available for two weeks post-event. The company is focused on ophthalmology, cardiology, and pulmonology, and is developing five product candidates currently in clinical trials.

4D Molecular Therapeutics (Nasdaq: FDMT) reported its Q3 2021 financial results and operational milestones. The company showcased promising clinical data for three product candidates, including 4D-310 for Fabry disease, which demonstrated significantly enhanced AGA enzyme activity. The company raised approximately $111 million through a follow-on stock offering, strengthening its financial position with cash and equivalents totaling $227 million. However, total revenue decreased to $1.4 million, compared to $7.4 million in the same quarter last year, primarily due to a terminated collaboration.

4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) has announced a public offering of 4,750,000 shares of its common stock at $25.00 per share, aiming for gross proceeds of approximately $118.8 million. The offering, which includes a 30-day option for underwriters to purchase an additional 712,500 shares, is set to close on November 2, 2021. The company focuses on targeted gene therapies and currently has five clinical candidates, including 4D-310 for Fabry disease and 4D-125 for XLRP.

4D Molecular Therapeutics (Nasdaq: FDMT) announced an underwritten public offering of 4,500,000 shares of its common stock, with a 30-day option for underwriters to purchase an additional 675,000 shares. The offering is managed by Goldman Sachs, SVB Leerink, and Evercore ISI. The registration statement is pending effectiveness with the SEC, and shares cannot be sold before this occurs. 4DMT is focused on targeted gene therapies for ophthalmology, cardiology, and pulmonology, advancing five product candidates currently in clinical development.

4D Molecular Therapeutics (FDMT) presented promising interim clinical data from its Phase 1/2 trial of 4D-310 for Fabry disease, marking the first clinical activity data from a product developed via their proprietary Therapeutic Vector Evolution platform. All three patients treated exhibited serum AGA enzyme activity significantly above the normal range, with increases of 25-fold in two cases. Safety data showed a manageable profile with no dose-limiting toxicities, although one patient experienced a transient adverse event. The company is committed to enrolling a diverse patient population moving forward.

4D Molecular Therapeutics (Nasdaq: FDMT) announced interim data from its Phase 1/2 clinical trial of 4D-125 for advanced X-linked retinitis pigmentosa (XLRP). The treatment was well tolerated in all 8 patients, showing no serious adverse events. Clinical activity was noted with reduced photoreceptor loss and improvements in retinal sensitivity. The company plans to continue patient enrollment in a higher dose cohort and explore treatment for less advanced patients. The results validate the therapeutic potential of their platform, with expectations for further developments in other products.